目的 建立普瑞巴林药物利用评价（DUE）标准，并以AHP-TOPSIS法评估普瑞巴林用药合理性，为普瑞巴林临床用药标准的制定提供参考。方法 根据专家共识、药品说明书等，制定普瑞巴林的合理性用药评价标准。从HIS系统中随机选取2022年1月1日—2024年12月31日使用普瑞巴林治疗的386例病例做合理性分析。结果 适应证、用量用法、给药方式、禁忌证、注意事项、不良反应的发生与处理、药物相互作用、经济性、医师权限指标、临床疗效评价的相对权重系数分别为17.765%、14.676%、7.482%、4.096%、10.580%、9.215%、15.700%、17.747%、1.365%、8.874%，其中适应证、经济性、药物相互作用的相对权重值较高；C_i值最高为100%，最低值为34.80%，C_i≥80%的病例为313例（81.09%），60%≤C_i＜80%为21例（5.44%），C_i＜60%为52例（13.47%），其中评价结果中适应证、禁忌证、注意事项、药物相互作用、经济性、医师权限指标、临床疗效评价7个评价指标在用药合理、基本合理及不合理评分进行比较，存在明显统计学差异（P＜0.05）；不合理用药主要集中在适应证、经济性、药物相互作用。结论 建立的普瑞巴林的DUE，且以AHP-TOPSIS法评价普瑞巴林临床治疗的合理性用药，评价结果准确、客观，并对普瑞巴林临床用药合理性评的价值较高。

Objective To establish DUE criteria for pregabalin and evaluate the appropriateness of its clinical use through the AHP-TOPSIS method, thereby providing a reference for the formulation of clinical medication standards for pregabalin.Methods Based on expert consensus and drug instructions, we developed evaluation criteria for the rational use of pregabalin. A total of 386 patient cases treated with pregabalin between January 1, 2022 to December 31, 2024, were randomly selected from the Hospital Information System (HIS) for rationality analysis.Results The relative weight coefficients for the evaluation indicators were as follows: indication (17.765%), dosage and administration (14.676%), route of administration (7.482%), contraindications (4.096%), precautions (10.580%), occurrence and management of adverse reactions (9.215%), drug interactions (15.700%), economic efficiency (17.747%), physician authority (1.365%), and clinical efficacy evaluation (8.874%). Among these, indication, economic efficiency, and drug interactions had higher relative weight values. The C_i value ranged from a maximum of 100% to a minimum of 34.80%. Cases with C_i ≥ 80% numbered 313 (81.09%), those with 60% ≤ C_i < 80% numbered 21 (5.44%), and those with C_i < 60% numbered 52 (13.47%). In the evaluation results, there were statistically significant differences (P < 0.05) in the scores for the following seven indicators: indication, contraindications, precautions, drug interactions, economic efficiency, physician authority, and clinical efficacy evaluation. Irrational medication use was mainly concentrated in the areas of indication, economic efficiency, and drug interactions.Conclusion The DUE for pregabalin established in this study, along with the AHP-TOPSIS method for evaluating the rational use of pregabalin in clinical treatment, provides accurate and Objective evaluation results. This approach holds significant value for assessing the rationality of pregabalin use in clinical settings.

R971

安徽省卫生健康科研项目（AHWJ2022c0225）